Latest Valneva SE (VALN) News on May 16, 2025
Pharmaceutical Technology
4 days ago
Valneva’s chikungunya vaccine use halted in older adults amid safety concerns
GlobeNewswire
5 days ago
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
GuruFocus.com
9 days ago
Valneva SE (INRLF) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...
GlobeNewswire
10 days ago
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
20 days ago
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
GlobeNewswire
a month ago
Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
Pharmaceutical Technology
a month ago
Valneva’s single-dose chikungunya vaccine authorised in Brazil
GlobeNewswire
a month ago
Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country
GlobeNewswire
a month ago
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above
GlobeNewswire
2 months ago
Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA
GlobeNewswire
2 months ago
Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program
GlobeNewswire
2 months ago
Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F
Pharmaceutical Technology
2 months ago
Valneva outlays 40,000 vaccines to Réunion amidst chikungunya surge
GuruFocus.com
2 months ago
Valneva SE (INRLF) (FY 2024) Earnings Call Highlights: Strong Sales Growth and Strategic ...
GlobeNewswire
2 months ago
Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook
GlobeNewswire
2 months ago
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
MT Newswires
3 months ago
Valneva Gets Label Extension Recommendation for Chikungunya Vaccine in Europe
GlobeNewswire
3 months ago
Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®
Pharmaceutical Technology
3 months ago
Valneva hits 2024 sales target but plans lower cash burn in 2025
GlobeNewswire
3 months ago
Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook
Pharmaceutical Technology
3 months ago
Bavarian Nordic scoops FDA approval for chikungunya vaccine in adults and teens
MT Newswires
3 months ago
Valneva Gets Marketing Authorization in UK for Chikungunya Vaccine; Shares Rise
GlobeNewswire
3 months ago
Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®
MT Newswires
4 months ago
Valneva Signs $33 Million Ixiaro Vaccine Supply Contract With US Defense Department; Shares Climb
GlobeNewswire
4 months ago
Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million
Clinical Trials Arena
4 months ago
Valneva announces positive outcomes from chikungunya vaccine trial
GlobeNewswire
4 months ago
Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
TipRanks
5 months ago
Valneva and Serum Institute of India Collaborate to Tackle Chikungunya in Asia
GlobeNewswire
5 months ago
Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India
MT Newswires
6 months ago
Valneva Submits Label Extension Application to US FDA for Chikungunya Vaccine IXCHIQ
GlobeNewswire
6 months ago
Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA
The Wall Street Journal
6 months ago
European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department
GlobeNewswire
6 months ago
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
GuruFocus.com
6 months ago
Valneva SE (INRLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved ...
GlobeNewswire
6 months ago
Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
7 months ago
Valneva to Present on Chikungunya at Several Leading Scientific Conferences
MT Newswires
7 months ago
Valneva, LimmaTech Get FDA Fast Track Designation for Shigellosis Vaccine Candidate
GlobeNewswire
7 months ago
Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V
GuruFocus.com
7 months ago
Valneva SE (INRLF) (H1 2024) Earnings Call Highlights: Navigating Growth Amidst Revenue Challenges
GlobeNewswire
7 months ago
Valneva SE - Declaration of shares and voting rights - September 30, 2024
GlobeNewswire
7 months ago
Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET
Pharmaceutical Technology
8 months ago
Valneva eyes teenage label for chikungunya vaccine in Europe and Canada
GlobeNewswire
8 months ago
Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada
GlobeNewswire
8 months ago
Valneva Announces the Success of its Private Placement Raising approximately €60 Million
GlobeNewswire
8 months ago
Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros
Clinical Trials Arena
8 months ago
Valneva and Pfizer report positive data from trial of Lyme disease vaccine booster
GlobeNewswire
8 months ago
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate
